These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1884142)

  • 21. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
    Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
    BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice.
    Reading J; Hall RR; Parmar MK
    Br J Urol; 1995 May; 75(5):604-7. PubMed ID: 7613798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
    Mulders PF; Meyden AP; Doesburg WH; Oosterhof GO; Debruyne FM
    Br J Urol; 1994 Apr; 73(4):403-8. PubMed ID: 8199828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preservation of the bladder in transitional cell tumors infiltrating the lamina propria].
    Benoît G; Alexandre L; Bensadoun H; Vieillefond A; Martin PR; Martin A; Jardin A
    Presse Med; 1991 Sep; 20(30):1425-8. PubMed ID: 1835025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy with bacille Calmette-Guérin in patients with superficial transitional cell carcinoma of the bladder associated with bilharziasis.
    Wishahi MM; Ismail IM; el-Sherbini M
    Br J Urol; 1994 Jun; 73(6):649-54. PubMed ID: 8032832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
    Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
    Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The management of superficial transitional cell carcinoma of the bladder.
    Sengupta S; Blute ML
    Urology; 2006 Mar; 67(3 Suppl 1):48-54; discussion 54-5. PubMed ID: 16530076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dystrophic bladder wall calcifications following intravesical BCG treatment for superficial transitional cell carcinoma of bladder.
    Spirnak JP; Lubke WL; Thompson IM; Lopez M
    Urology; 1993 Jul; 42(1):89-92. PubMed ID: 8328131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments.
    Jauhiainen K; Rintala E
    Ann Chir Gynaecol Suppl; 1993; 206():31-8. PubMed ID: 8291866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bladder tumors].
    Egli U
    Ther Umsch; 1996 Sep; 53(9):697-701. PubMed ID: 8966698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies?
    Morris SB; Gordon EM; Shearer RJ; Woodhouse CR
    Br J Urol; 1995 Feb; 75(2):193-6. PubMed ID: 7850325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The management of T1G3 bladder cancer.
    Bogdanović J; Marusić G; Djozić J; Sekulić V; Budakov P; Dejanović N; Stojkov J
    Urol Int; 2002; 69(4):263-5. PubMed ID: 12444280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma.
    Colombo R; Da Pozzo LF; Salonia A; Rigatti P; Leib Z; Baniel J; Caldarera E; Pavone-Macaluso M
    J Clin Oncol; 2003 Dec; 21(23):4270-6. PubMed ID: 14581436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coincident vesical transitional cell carcinoma and prostatic carcinoma. Clinical features and treatment.
    Androulakakis PA; Schneider HM; Jacobi GH; Hohenfellner R
    Br J Urol; 1986 Apr; 58(2):153-6. PubMed ID: 3697629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follow-up of the effect of BCG vaccine treatment in bladder tumour patients.
    Kulcsár G; Nász I; Tenke P; Csata S
    Acta Microbiol Hung; 1993; 40(2):151-7. PubMed ID: 8184669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.
    Holmäng S; Hedelin H; Anderström C; Johansson SL
    J Urol; 1995 Jun; 153(6):1823-6; discussion 1826-7. PubMed ID: 7752327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
    Schellhammer PF; Ladaga LE; Fillion MB
    J Urol; 1986 Feb; 135(2):261-4. PubMed ID: 3511283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.